Segment Reporting

Sales

1,349.1

1,241.1

2,685.4

2,459.6

113.4

102.8

220.3

210.2

Royalty and commission income*

101.4

77.9

171.9

174.1

0.5

1.3

1.2

1.4

Total revenues

1,450.5

1,319.0

2,857.3

2,633.7

113.9

104.1

221.5

211.7

Gross margin

1,218.8

1,101.4

2,405.3

2,227.6

78.4

71.2

151.3

144.6

Marketing and selling expenses*

–379.0

–337.7

–701.2

–655.8

–63.1

–47.3

–119.8

–100.5

Royalty and commission expenses*

–113.1

–98.9

–230.0

–193.2

–0.5

–0.4

–0.7

–0.8

Administration expenses

–69.0

–66.4

–131.3

–132.9

–6.0

–6.7

–11.9

–12.6

Other operating expenses and income

–54.8

–28.0

–119.9

–82.8

–7.2

–0.9

–9.8

–2.0

Research and development

–296.1

–302.3

–600.6

–574.2

–6.1

–4.2

–10.9

–8.5

Operating result

163.6

124.7

341.6

300.3

–5.4

10.4

–3.9

18.3

Exceptional items

–

–

–

–70.0

–

–

–

–

Earnings before interest and tax (EBIT)

163.6

124.7

341.6

230.3

–5.4

10.4

–3.9

18.3

Net operating assets**

–

–

10,932.5

10,015.9

–

–

338.8

336.0

Segment liabilities**

–

–

–1,176.7

–1,078.2

–

–

–79.3

–76.9

Capital spending on property, plant and equipment

61.9

69.8

108.0

121.0

0.9

1.8

2.3

5.1

Investments in intangible assets

11.8

11.6

23.3

31.4

0.5

0.5

0.7

0.9

Depreciation

–188.5

–185.7

–370.3

–374.3

–3.3

–1.7

–6.1

–4.0

Impairment losses

–

–

–17.2

–

–

–

–

–

Net cash flows from operating activities

328.9

218.1

575.0

519.2

3.4

16.0

2.2

22.8

Net cash flows from investing activities

–71.4

–77.6

–126.1

–151.4

–2.3

–1.5

–3.6

–5.1

Free cash flow

257.5

140.4

448.9

367.8

1.1

14.6

–1.4

17.7

Underlying free cash flow

257.5

140.4

448.9

367.8

1.1

14.6

–1.4

17.7

FCR in %

17.8

10.6

15.7

14.0

1.0

14.0

–0.6

8.4

ROS in %

11.3

9.5

12.0

11.4

–4.8

10.0

–1.8

8.6

Pharmaceuticals

EUR million

Q2
2010

Q2
2009

Jan.–June
2010

Jan.–June
2009

Sales

1,462.5

1,343.9

2,905.6

2,669.9

Royalty and commission income*

101.9

79.2

173.1

175.5

Total revenues

1,564.4

1,423.1

3,078.7

2,845.4

Gross margin

1,297.2

1,172.6

2,556.6

2,372.2

Marketing and selling expenses*

–442.1

–385.0

–821.1

–756.2

Royalty and commission expenses*

–113.6

–99.3

–230.6

–194.0

Administration expenses

–75.0

–73.1

–143.3

–145.4

Other operating expenses and income

–62.0

–29.0

–129.7

–84.8

Research and development

–302.2

–306.5

–611.5

–582.7

Operating result

158.2

135.1

337.7

318.6

Exceptional items

–

–

–

–70.0

Earnings before interest and tax (EBIT)

158.2

135.1

337.7

248.6

Net operating assets**

–

–

11,271.2

10,351.9

Segment liabilities**

–

–

–1,256.0

–1,155.1

Capital spending on property, plant and equipment

62.9

71.6

110.3

126.1

Investments in intangible assets

12.3

12.2

24.1

32.3

Depreciation

–191.8

–187.4

–376.4

–378.3

Impairment losses

–

–

–17.2

–

Net cash flows from operating activities

332.3

234.1

577.2

542.0

Net cash flows from investing activities

–73.7

–79.1

–129.7

–156.5

Free cash flow

258.6

155.0

447.5

385.5

Underlying free cash flow

258.6

155.0

447.5

385.5

FCR in %

16.5

10.9

14.5

13.5

ROS in %

10.1

9.5

11.0

11.2

Sales

282.8

187.2

518.2

315.2

357.6

295.3

701.7

598.2

Royalty and commission income*

0.9

1.8

4.4

5.0

2.3

2.3

3.8

4.3

Total revenues

283.7

189.0

522.6

320.2

359.9

297.6

705.5

602.6

Gross margin

204.2

87.8

366.9

143.5

189.3

131.6

379.5

278.0

Marketing and selling expenses*

–8.4

–6.5

–15.1

–12.9

–89.4

–75.3

–170.9

–151.1

Royalty and commission expenses*

–1.9

0.1

–4.3

–0.2

–1.8

–2.0

–4.6

–4.4

Administration expenses

–4.8

–4.4

–8.9

–8.9

–17.4

–16.1

–33.1

–32.2

Other operating expenses and income

–14.5

–2.1

–27.6

–10.7

–19.3

–7.3

–39.3

–20.3

Research and development

–22.7

–22.2

–46.5

–44.4

–13.8

–12.3

–28.1

–26.3

Operating result

151.1

51.8

262.9

64.4

47.2

17.9

102.1

42.4

Exceptional items

–

–

–

–

–

–

–

1.2

Earnings before interest and tax (EBIT)

151.1

51.8

262.9

64.4

47.2

17.9

102.1

43.6

Net operating assets**

–

–

941.6

837.4

–

–

1,230.6

1,120.0

Segment liabilities**

–

–

–82.6

–78.6

–

–

–175.6

–151.6

Capital spending on property, plant and equipment

13.0

13.5

19.5

28.4

15.3

15.7

25.8

35.3

Investments in intangible assets

0.3

1.2

0.6

2.7

2.0

2.1

3.0

4.9

Depreciation

–16.3

–14.7

–32.3

–29.3

–18.8

–17.3

–37.9

–34.8

Impairment losses

–7.4

–

–16.4

–

–

–0.2

–

–0.2

Net cash flows from operating activities

138.9

73.7

249.3

115.4

73.7

67.8

108.9

82.7

Net cash flows from investing activities

–13.0

–14.6

–19.7

–30.9

–17.0

–16.8

–29.6

–38.8

Free cash flow

125.9

59.1

229.5

84.5

56.7

51.0

79.4

43.9

Underlying free cash flow

125.9

59.1

229.5

84.5

56.7

51.0

79.4

43.9

FCR in %

44.4

31.3

43.9

26.4

15.8

17.1

11.2

7.3

ROS in %

53.2

27.4

50.3

20.1

13.1

6.0

14.5

7.0

Merck Millipore

Chemicals

EUR million

Q2
2010

Q2
2009

Jan.–June
2010

Jan.–June
2009

Q2
2010

Q2
2009

Jan.–June
2010

Jan.–June
2009

Sales

–

–

–

–

640.3

482.4

1,220.0

913.4

Royalty and commission income*

–

–

–

–

3.3

4.1

8.2

9.4

Total revenues

–

–

–

–

643.6

486.6

1,228.1

922.8

Gross margin

–

–

–

–

393.5

219.4

746.4

421.5

Marketing and selling expenses*

–

–

–

–

–97.8

–81.8

–185.9

–164.0

Royalty and commission expenses*

–

–

–

–

–3.7

–1.9

–8.9

–4.6

Administration expenses

–

–

–

–

–22.3

–20.5

–42.0

–41.1

Other operating expenses and income

–32.2

–

–32.2

–

–66.1

–9.4

–99.1

–31.0

Research and development

–

–

–

–

–36.5

–34.5

–74.5

–70.7

Operating result

–32.2

–

–32.2

–

166.0

69.7

332.8

106.8

Exceptional items

–

–

–

–

–

–

–

1.2

Earnings before interest and tax (EBIT)

–32.2

–

–32.2

–

166.0

69.7

332.8

108.0

Net operating assets**

–

–

–22.1

–

–

–

2,150.1

1,957.4

Segment liabilities**

–

–

–22.1

–

–

–

–280.3

–230.2

Capital spending on property, plant and equipment

–

–

–

–

28.2

29.2

45.3

63.7

Investments in intangible assets

–

–

–

–

2.3

3.2

3.6

7.6

Depreciation

–

–

–

–

–35.1

–32.0

–70.2

–64.1

Impairment losses

–

–

–

–

–7.4

–0.2

–16.4

–0.2

Net cash flows from operating activities

–8.6

–

–8.6

–

204.0

141.5

349.6

198.1

Net cash flows from investing activities

–

–

–

–

–30.0

–31.3

–49.3

–69.8

Free cash flow

–8.6

–

–8.6

–

174.0

110.1

300.3

128.3

Underlying free cash flow

–8.6

–

–8.6

–

174.0

110.1

300.3

128.3

FCR in %

–

–

–

–

27.0

22.6

24.5

13.9

ROS in %

–

–

–

–

25.8

14.3

27.1

11.6

Sales

–

–

–

–

Royalty and commission income*

–

–

–

–

Total revenues

–

–

–

–

Gross margin

–

–

–

–

Marketing and selling expenses*

–0.3

0.1

–1.4

–0.4

Royalty and commission expenses*

–

–

–

–

Administration expenses

–17.9

–14.5

–34.2

–28.4

Other operating expenses and income

18.6

–6.3

–15.5

–14.1

Research and development

–0.1

0.3

–

–0.1

Operating result

2.0

–20.3

–49.5

–42.9

Exceptional items

–1.2

–

–1.2

–

Earnings before interest and tax (EBIT)

0.8

–20.3

–50.7

–42.9

Net operating assets**

–

–

43.1

37.4

Segment liabilities**

–

–

–13.8

–15.7

Capital spending on property, plant and equipment

0.1

–0.1

0.3

–0.1

Investments in intangible assets

2.4

2.9

3.3

5.4

Depreciation

–0.5

–0.4

–1.1

–1.4

Impairment losses

–

–

–

–

Net cash flows from operating activities

–70.1

–183.2

–181.9

–265.1

Net cash flows from investing activities

–8.8

–789.7

1,336.0

–1,040.4

Free cash flow

–76.2

–185.9

–196.7

–270.6

Underlying free cash flow

–72.7

–185.9

–181.3

–270.6

FCR in %

–

–

–

–

ROS in %

–

–

–

–

Merck Group

EUR million

Q2
2010

Q2
2009

Jan.–June
2010

Jan.–June
2009

Sales

2,102.8

1,826.4

4,125.6

3,583.3

Royalty and commission income*

105.2

83.4

181.3

184.9

Total revenues

2,208.0

1,909.7

4,306.9

3,768.2

Gross margin

1,690.8

1,392.0

3,303.0

2,793.7

Marketing and selling expenses*

–540.2

–466.7

–1,008.4

–920.6

Royalty and commission expenses*

–117.3

–101.2

–239.5

–198.6

Administration expenses

–115.2

–108.1

–219.6

–214.9

Other operating expenses and income

–109.4

–44.7

–244.4

–129.8

Research and development

–338.8

–340.6

–686.0

–653.5

Operating result

326.2

184.5

621.0

382.6

Exceptional items

–1.2

–

–1.2

–68.8

Earnings before interest and tax (EBIT)

325.0

184.5

619.8

313.8

Net operating assets**

–

–

13,464.4

12,346.7

Segment liabilities**

–

–

–1,550.1

–1,401.0

Capital spending on property, plant and equipment

91.2

100.6

155.9

189.7

Investments in intangible assets

17.0

18.3

31.0

45.3

Depreciation

–227.4

–219.8

–447.6

–443.8

Impairment losses

–7.4

–0.2

–33.6

–0.2

Net cash flows from operating activities

466.2

192.3

744.9

475.0

Net cash flows from investing activities

–112.5

–900.2

1,157.0

–1,266.6

Free cash flow

356.4

79.2

551.2

243.2

Underlying free cash flow

359.9

79.2

566.5

243.2

FCR in %

16.3

4.1

13.2

6.5

ROS in %

14.8

9.7

14.4

10.2